Cytokinetics
CYTK
276 hedge funds and large institutions have $5.08B invested in Cytokinetics in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 111 increasing their positions, 84 reducing their positions, and 23 closing their positions.
405% more call options, than puts
Call options by funds: $50.9M | Put options by funds: $10.1M
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
32% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 84
22% more capital invested
Capital invested by funds: $4.16B → $5.08B (+$914M)
5% more funds holding
Funds holding: 262 → 276 (+14)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
12.51% less ownership
Funds ownership: 123.61% → 111.11% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$55.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$41.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$200M |
| 2 |
Lazard Asset Management
New York
|
-$79.3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$30M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$24M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$23.2M |
CYTK Hedge Fund Activity: Q3 2022 in Review
276 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2022, worth a combined $5.08B — up 22% from $4.16B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CYTK positions and 23 closed out — a net gain of 16 holders — while 111 added to existing stakes and 84 trimmed.
The largest buyer was BlackRock, adding an estimated $55.7M. The largest seller was Citadel Advisors, cutting an estimated $200M.
- 276 institutional investors held Cytokinetics (CYTK) as of Q3 2022, up from 262 in Q2 2022.
- Funds reported $5.08B of Cytokinetics stock for Q3 2022, up 22% quarter-over-quarter.
- 39 funds opened new Cytokinetics positions in Q3 2022 and 23 closed out, a net change of +16 holders.
- The largest Cytokinetics buyer in Q3 2022 was BlackRock, an estimated $55.7M added.
- The largest Cytokinetics seller in Q3 2022 was Citadel Advisors, an estimated $200M sold.
Based on aggregated 13F filings for Q3 2022.